Qlaris Phase 2 Study of QLS-111 in Combination With a PGA in OAG and/or OHT Patients

Conditions: Open-angle Glaucoma (OAG); Ocular Hypertension (OHT); Glaucoma Interventions: Drug: QLS-111, 0.015%; Drug: QLS-111, 0.030%; Drug: QLS-111, 0.075%; Drug: QLS-111 vehicle ophthalmic solution Sponsors: Qlaris Bio, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials